Heartbeam, Inc. Common Stock (BEAT) is a publicly traded Healthcare sector company. As of May 21, 2026, BEAT trades at $0.92 with a market cap of $53.25M and a P/E ratio of -1.51. BEAT moved +1.75% today. Year to date, BEAT is -66.51%; over the trailing twelve months it is -44.72%. Its 52-week range spans $0.54 to $4.00. Analyst consensus is strong buy with an average price target of $4.50. Rallies surfaces BEAT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
HeartBeam Advances U.S. Commercial Launch, Raises $11.5M, Cuts Q1 Loss to $4.7M: HeartBeam launched its initial commercial partnerships in major U.S. markets and advanced its FDA-cleared 3D ECG platform with progress on heart attack detection and ambulatory patch initiatives. The April public offering raised $11.5 million and Q1 net loss narrowed to $4.7 million from $5.5 million year-on-year.
| Metric | Value |
|---|---|
| Price | $0.92 |
| Market Cap | $53.25M |
| P/E Ratio | -1.51 |
| EPS | $-0.62 |
| Dividend Yield | 0.00% |
| 52-Week High | $4.00 |
| 52-Week Low | $0.54 |
| Volume | 688 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-21.02M |
| Gross Margin | 0.00% |
6 analysts cover BEAT: 0 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $4.50.